Dendreon Gets A Go Sign On Provenge - Forbes.com

[Guest guest]

http://www.forbes.com/markets/2008/01/15/dendreon-provenge-closer-markets-equity-cx_ml_0115markets35.html

While

American prostate cancer patients anxiously await approval of Dendreon's Provenge in the U.S., European authorities helped alleviate the

suffering of afflicted men on the other side of the Atlantic.

Dendreon (nasdaq: DNDN

- news -

people

) announced Tuesday that European authorities have granted Provenge a broad

patent. The patent covers Provenge, a prostate cancer vaccine candidate, as

well as similar drug candidates using the same active cellular immunotherapy

technology.

" While

our priority is to obtain the approval of Provenge in the U.S., the

issuance of this key patent solidifies the commercial potential of Provenge and

our ACI platform on a more international basis, " said

Gold, chief executive of Dendreon.